EC Number   |
Substrates  |
Organism |
Products |
Reversibility |
|---|
   3.4.23.36 | more |
no activity with tumor necrosis factor-alpha, neuregulin 1 type III and Bri2 |
Mus musculus |
? |
- |
? |
| 3.4.23.36 | more |
indispensability of the cysteine residue for modification and processing, glycine at the -1 position can be replaced by alanine or serine, however, mutant prolipoprotein with leucine or isoleucine substitution at the -1 position are modified and consequently not processed, whereas a glycine to threonine substitution at the -1 position allows modification at a slower rate, but does not allow processing of the lipid-modified mutant prolipoprotein |
Escherichia coli B / ATCC 11303 |
? |
- |
? |
| 3.4.23.36 | more |
processing of the lipid-modified prolipoproteins |
Escherichia coli B / ATCC 11303 |
? |
- |
? |
| 3.4.23.36 | more |
lipoprotein processing by LspA is required for virulence of the organism and acts as virulence determinant of tuberculosis |
Mycobacterium tuberculosis H37Rv |
? |
- |
? |
| 3.4.23.36 | Murein prolipoprotein + H2O |
cleavage of Gly-diacylglyceryl-cysteine bond, also cleavage of this bond in the majority of other lipoprotein precursors, some prolipoproteins contain Ala-diacylglyceryl-cysteine, or Ser-diacylglyceryl-cysteine cleavage sites |
Escherichia coli |
? |
- |
? |
| 3.4.23.36 | Murein prolipoprotein + H2O |
cleavage of Gly-diacylglyceryl-cysteine bond, also cleavage of this bond in the majority of other lipoprotein precursors, some prolipoproteins contain Ala-diacylglyceryl-cysteine, or Ser-diacylglyceryl-cysteine cleavage sites |
Escherichia coli B / ATCC 11303 |
? |
- |
? |
| 3.4.23.36 | phospholamban + H2O |
- |
Mus musculus |
? |
- |
? |
| 3.4.23.36 | pre-PrsA + H2O |
- |
Bacillus subtilis |
PrsA protein + ? |
- |
? |
| 3.4.23.36 | prolipoprotein + H2O |
- |
Escherichia coli |
? |
- |
? |
| 3.4.23.36 | prolipoprotein + H2O |
- |
Escherichia coli B / ATCC 11303 |
? |
- |
? |
